PAXMAN can today confirm that the clinically proven Paxman Scalp Cooling System will soon be made available to patients being treated for breast cancer at Memorial Sloan Kettering Cancer Center (MSK).

With extensive global experience the Paxman Scalp Cooling System is the only FDA cleared scalp cooling system based on a randomized clinical trial. PAXMAN will install 34 systems across 10 MSK outpatient facilities in the New York City area.  Deliveries will commence through December, with implementation beginning in early 2018. As part of the implementation process up to 500 healthcare professionals will follow the PAXMAN Training Plan to ensure scalp cooling protocols are effectively followed ensuring the best possible hair retention outcomes for patients.

“Our vision is to give all breast cancer patients the choice to retain their hair during their chemotherapy treatment. We are delighted to be able to empower these women and offer them a degree of control.” says CEO Richard Paxman.